Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“First line adagrasib + pembrolizumab for metastatic NSCLC with PDL1>50% and KRAS G12 C: Krystal 7 phase 2 study”
More posts featuring Akhil Santhosh.
